seekingalpha.com Market update
Argenx advances as Vyvgart hits key trial endpoints for autoimmune myositis
[Chemistry.] artisteer/iStock via Getty Images * Shares in Argenx SE (ARGX [https://seekingalpha.com/symbol/ARGX]) jumped on Monday after the European biotech reported the latest large, successful trial for its blockbuster drug Vyvgart. * The drug helped patients with autoimmune myositis, a disease in which the immune system attacks the muscles and can quickly rob patients of their independence, Argenx said …